nVerses Capital LLC Invests $26,000 in Pulmonx Co. (NASDAQ:LUNG)

nVerses Capital LLC purchased a new stake in Pulmonx Co. (NASDAQ:LUNG) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,100 shares of the company’s stock, valued at approximately $26,000.

Other large investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Pulmonx in the 3rd quarter worth about $102,000. Cubist Systematic Strategies LLC grew its stake in Pulmonx by 141.6% in the second quarter. Cubist Systematic Strategies LLC now owns 109,105 shares of the company’s stock worth $692,000 after purchasing an additional 63,945 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Pulmonx in the second quarter valued at about $37,000. Susquehanna Fundamental Investments LLC acquired a new stake in Pulmonx during the second quarter valued at approximately $477,000. Finally, Mackenzie Financial Corp bought a new position in Pulmonx during the 2nd quarter worth approximately $102,000. 91.04% of the stock is currently owned by institutional investors.

Insider Activity at Pulmonx

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,586 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the completion of the transaction, the insider now owns 295,433 shares in the company, valued at approximately $1,979,401.10. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Pulmonx news, CEO Steven S. Williamson bought 14,245 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were purchased at an average price of $6.84 per share, with a total value of $97,435.80. Following the purchase, the chief executive officer now directly owns 219,531 shares of the company’s stock, valued at approximately $1,501,592.04. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total value of $30,726.20. Following the transaction, the insider now owns 295,433 shares of the company’s stock, valued at $1,979,401.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,351 shares of company stock worth $361,494 in the last ninety days. 5.70% of the stock is owned by insiders.

Pulmonx Stock Performance

Shares of NASDAQ LUNG opened at $6.13 on Thursday. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $14.84. The company has a market cap of $237.94 million, a price-to-earnings ratio of -3.98 and a beta of 0.64. The company has a current ratio of 8.97, a quick ratio of 7.92 and a debt-to-equity ratio of 0.37. The stock’s 50 day simple moving average is $7.31 and its 200 day simple moving average is $7.34.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. The company had revenue of $20.78 million for the quarter, compared to analysts’ expectations of $20.23 million. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. Equities research analysts expect that Pulmonx Co. will post -1.64 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on LUNG shares. Canaccord Genuity Group boosted their price target on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company lowered their target price on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.